Aimmune Therapeutics

136 articles with Aimmune Therapeutics

• Aimmune to Present at the Cantor Global Healthcare Conference

  9/26/2019

  Aimmune Therapeutics, Inc. announced that its President and Chief Executive Officer, Jayson Dallas, M.D., will present at the Cantor Global Healthcare Conference on Thursday, October 3, 2019 at 8:20 a.m. E.T. in New York City.

• 

  Aimmune Eyes 2020 Approval of Peanut Allergy Treatment

  9/19/2019

  Aimmune’s peanut allergy treatment is one-step closer to approval following strong support from the Allergenic Products Advisory Committee, which overwhelmingly recommended approval of Palforzia, the proposed trade name of the investigational oral treatment, AR101.

• FDA Allergenic Products Advisory Committee Votes to Support the Use of Aimmune’s PALFORZIA™ (AR101) for Peanut Allergy

  9/13/2019

  Aimmune Therapeutics, Inc. announced that the Allergenic Products Advisory Committee convened by the U.S. Food and Drug Administration voted to support the use of AR101 in children and teens with peanut allergy.

• Aimmune Stock Trading Halted Today; FDA Allergenic Products Advisory Committee (APAC) Meeting to Discuss PALFORZIA™ (AR101) for Peanut Allergy

  9/13/2019

  Aimmune Therapeutics, Inc. announced that NASDAQ has halted trading of the company’s common stock.

• Aimmune to Participate in Three Investor Conferences in September - Aug. 28, 2019

  8/28/2019

  Aimmune Therapeutics, Inc. announced that members of the Aimmune executive management team will participate in three upcoming investor conferences in September

• Aimmune Enrolls First Patient in Phase 2 Trial of AR201 for Egg Allergy

  8/21/2019

  Aimmune Therapeutics, Inc. announced that it has randomized its first patient in a phase 2 clinical trial of AR201 for the treatment of egg allergy.

• Aimmune Therapeutics Announces Second Quarter 2019 Financial Results and Provides Operational Highlights

  8/8/2019

  Aimmune Therapeutics, Inc. announced financial results for the quarter and six months ended June 30, 2019.

• Aimmune to Present at the Wedbush PacGrow Healthcare Conference

  8/6/2019

  Jayson Dallas, M.D., will present at the Wedbush PacGrow Healthcare Conference on Tuesday, August 13, 2019, at 3:05 p.m. E.T. in New York City.

• Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Second Quarter 2019 Financial Results and Recent Operational Highlights

  8/1/2019

  Aimmune Therapeutics, Inc., a biopharmaceutical company developing treatments for life-threatening food allergies, announced that it will host a conference call on Thursday, August 8, 2019, at 4:30 p.m. ET to discuss its financial results for the quarter ended June 30, 2019, and recent operational highlights.

• Aimmune Statement on Institute for Clinical and Economic Review (ICER) Final Report on AR101 for Peanut Allergy

  7/11/2019

  Exclusion of long-term desensitization and patient quality-of-life data by ICER fails to recognize the full value AR101 immunotherapy can deliver to the peanut allergy community

• 

  BioSpace Global Roundup: July 3

  7/3/2019

  Companies from across the globe provide information on agreements and pipeline updates.

• Aimmune Submits Marketing Authorization Application to European Medicines Agency for AR101 for Peanut Allergy

  6/28/2019

  Aimmune Therapeutics, Inc. announced that it has submitted a Marketing Authorization Application to the European Medicines Agency for AR101, an investigational biologic oral immunotherapy to reduce the frequency and severity of allergic reactions following exposure to peanuts in children and adolescents ages 4 to 17.

• Aimmune to Present at the JMP Securities Life Sciences Conference

  6/12/2019

  Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas, M.D., will present at the JMP Securities Life Sciences Conference on Wednesday, June 19, 2019 at 2:30 p.m. E.T. in New York

• Aimmune Therapeutics Discusses AR101’s Cost-Effectiveness and Demonstrated Clinical Benefits at ICER Meeting

  6/11/2019

  Company to Share Updated Clinical Data on AR101 and Provide Perspective on Its Value to Society

• Aimmune to Participate in the Goldman Sachs 40th Annual Healthcare Conference

  6/5/2019

  Aimmune Therapeutics, Inc. announced that members of its Executive Management Team will participate in a fireside chat at the Goldman Sachs 40th Annual Healthcare Conference on Wednesday, June 12, 2019 at 9:20 a.m. P.D.T.

• New Data from Phase 3 PALISADE Follow-on Study of AR101 for Peanut Allergy Show Continued Immunomodulation Through Daily Dosing Beyond One Year

  6/4/2019

  Aimmune Therapeutics, Inc. announced results from ARC004, an open-label, rollover study of the landmark Phase 3 PALISADE trial, which showed that extending daily therapy with AR101 by an additional 28 weeks led to improved tolerability with lower numbers of adverse events compared to the PALISADE therapeutic dosing period, an increase in the amount of peanut that could be safely ingested, and continued immunomodulation to peanut protein in most patients.

• Data from Two Studies Confirm Quality of Life and Psychosocial Burden of Living with Peanut Allergy

  6/4/2019

  Aimmune Therapeutics, Inc., a biopharmaceutical company developing treatments for life-threatening food allergies, announced new data from two studies that assessed the psychosocial burden of living with peanut allergy.

• 

  Continued Dosing of Peanut Allergy Therapy Leads to Greater Tolerance, Trial Data Shows

  6/4/2019

  The add-on data showed that longer treatment with AR101 provided higher tolerance levels to peanut protein.

• Pivotal Phase 3 ARTEMIS Trial Data Demonstrates Consistent Safety and Efficacy of AR101 in Children and Adolescents with Peanut Allergy

  6/2/2019

  Aimmune Therapeutics, Inc. presented topline results from the pivotal European Phase 3 ARTEMIS clinical trial, which it previously announced had met its primary endpoint, demonstrating the efficacy and safety of AR101 in peanut-allergic children and adolescents after six months of dose escalation and a three-month therapeutic dosing phase.

• Aimmune to Present AR101 Data at European Academy of Allergy and Clinical Immunology 2019 Congress

  5/24/2019

  Full Results from Phase 3 ARTEMIS Study Will Be Featured